Drug intelligence / Profile preview

C-MOH-01

Development stage: Unknown
Lead developer: Curatis
Modality: Small Molecules

Overview

C-MOH-01 is a small molecule drug under development by Curatis for the treatment of medication overuse headache (MOH) and tension-type headache. It is classified as a central nervous system (CNS) drug. Medication overuse headache is a chronic daily headache condition that develops in patients with pre-existing primary headache disorders who overuse acute headache medications. While the specific biological target and mechanism of action remain undisclosed, the drug has progressed into clinical development to address the underlying pathophysiology of these chronic headache disorders.

Beyond the preview

Go deeper on C-MOH-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-MOH-01.

Explore the full profile